scholarly journals The role of 18FDG PET/CT in evaluation of unknown primary tumors

2019 ◽  
Vol 70 (1) ◽  
pp. 39-42
Author(s):  
Bogdan Marković ◽  
Dragana Šobić-Šaranović
Keyword(s):  
Unknown Primary ◽  
Primary Tumors ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Unknown Primary Tumors

scholarly journals Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT

2011 ◽  
Vol 4 (1) ◽  
Author(s):  
Jong Sun Park ◽  
Jae-Joon Yim ◽  
Won Jun Kang ◽  
June-Key Chung ◽  
Chul-Gyu Yoo ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Unknown Primary ◽  
Primary Tumors ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Unknown Primary Tumors

Role of pet/ct in detection of tumor of unknown origin

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Khadija R Elsayed ◽  
Khaled E Allam ◽  
Omar F Kamel ◽  
Ahmed H Soliman ◽  
Huda F Elsayed
Keyword(s):  
Primary Tumor ◽  
Predictive Value ◽  
Unknown Origin ◽  
Whole Body ◽  
Unknown Primary ◽  
Primary Tumors ◽  
Negative Results ◽  
Number Of Patients ◽  
Pet Ct

Abstract Purpose To evaluate the role of combined positron emission tomography and computed tomography (PET/CT) imaging in the detection of tumors of unknown origin. Methods This study included 20 cases presented with pathologically proved metastases of unknown primary or with clinic-radiological suspicion of metastases with unknown primary. Results The number of patients with true positive primary tumor sites was 14 (70%), 2 patients with false-positive results (10%), 2 patients with true negative results (10%) and 2 patients with false-negative results (10%). A sensitivity of 87.5% was achieved, with a specificity of 50% and a total accuracy of 80%. The Positive predictive value was 87.5%%, while the negative predictive value was 50%. The detection rate of the origin of the primary tumor was 70%. Conclusion whole-body FDG-PET/CT has to be considered a useful tool in evaluating metastases from UPT, allowing identification of primary tumors and modifying the stage of the disease and affect the management.

Unknown Primary Tumors: Detection with Dual-Modality PET/CT—Initial Experience

Radiology ◽  
2005 ◽  
Vol 234 (1) ◽  
pp. 227-234 ◽  
Author(s):  
Andreas Gutzeit ◽  
Gerald Antoch ◽  
Hilmar Kühl ◽  
Thomas Egelhof ◽  
Markus Fischer ◽  
...  
Keyword(s):  
Unknown Primary ◽  
Initial Experience ◽  
Primary Tumors ◽  
Dual Modality ◽  
Pet Ct ◽  
Unknown Primary Tumors

scholarly journals The Usefulness of PET/CT In Detecting and Managing Cancers With Unknown Primary Site Depends on Histological Subtype

2021 ◽  
Author(s):  
Ella Nissan ◽  
Uri Amit ◽  
Leo Baron ◽  
Amit Zabatani ◽  
Damian Urban ◽  
...  
Keyword(s):  
Primary Site ◽  
Unknown Primary ◽  
Histological Subtype ◽  
Unknown Primary Site ◽  
Primary Tumors ◽  
Poorly Differentiated Carcinoma ◽  
Pet Ct ◽  
Poorly Differentiated ◽  
The Mean

Abstract Introduction: We assessed the role of PET/CT in identifying and managing cancer of unknown primary site (CUP). Methods: We reviewed 64 patients' PET/CT scans with CUP performed during 2012–2019. Results: The median age was 65 years. Of 138-FDG-avid lesions, the mean SUVmax was10.6±6.0. Primary tumors (PT) were detected in 28(44%) patients. Detection was positive in only one(10%) patient with squamous cell carcinoma (SCC) histology, compared to 4/14(29%) with poorly differentiated carcinoma, 4/9(44%) with adenocarcinoma, 18/30(60%) of those for whom the origin could be presumed (p= 0.034 for SCC compared to other histologies). The mean age, mean SUVmax, and the distribution of organ involvement were similar between patients with and without discovered PTs, and also between patients with SCC and with the other histologies combined. However, those with SCC were less likely than the others to present with multi-lesion involvement, p<0.001. PET/CT interpretations apparently affected treatment of 8/28(29%) patients with PT detected and in none of the 35 whose PT was not discovered, p<0.001. Conclusion: PET/CT detected PT in almost half of CUP. However, it did not appear beneficial in those with SCC histology. PET/CT showed limited overall value in guiding clinical management but benefited a subgroup with discovered PT.

scholarly journals Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT

2021 ◽  
Author(s):  
Stefan A. Koerber ◽  
R. Finck ◽  
K. Dendl ◽  
M. Uhl ◽  
T. Lindner ◽  
...  
Keyword(s):  
Hybrid Imaging ◽  
Background Activity ◽  
The Novel ◽  
Malignant Tissue ◽  
Primary Tumors ◽  
Aggressive Disease ◽  
Standardized Uptake Values ◽  
Pet Ct ◽  
Pet Scans

Abstract Purpose A high expression of fibroblast activation protein (FAP) was observed in multiple sarcomas, indicating an enormous potential for PET/CT using 68Ga-radiolabeled inhibitors of FAP (FAPI). Therefore, this retrospective study aimed to evaluate the role of the novel hybrid imaging probe for sarcomas as a first clinical evaluation. Methods A cohort of 15 patients underwent 68Ga-FAPI-PET/CT for staging or restaging. The acquisition of PET scans was performed 60 min after administration of 127 to 308 MBq of the tracer. The uptake of 68Ga-FAPI in malignant tissue as well as in healthy organs was quantified by standardized uptake values SUVmean and SUVmax. Results Excellent tumor-to-background ratios (> 7) could be achieved due to low background activity and high SUVmax in primary tumors (median 7.16), local relapses (median 11.47), and metastases (median 6.29). The highest uptake was found for liposarcomas and high-grade disease (range 18.86–33.61). A high SUVmax (> 10) was observed for clinically more aggressive disease. Conclusion These preliminary findings suggest a high potential for the clinical use of 68Ga-FAPI-PET/CT for patients diagnosed with sarcoma.

Sign in / Sign up

Export Citation Format

Share Document